title: Frequency of and Risk Factors for Acute Kidney Injury Associated With Vancomycin Use in the Pediatric Intensive Care Unit.
abstract: BACKGROUND:Published information evaluating frequency of and risk factors for vancomycin-induced acute kidney injury (AKI) in the pediatric intensive care unit (PICU) population is conflicting.OBJECTIVES:The primary objective was to describe the proportion of our PICU patients who developed AKI with intravenous (IV) vancomycin. The secondary objective was to describe the associated potential risk factors.METHODS:Pediatric patients (0-18 years) who received their first IV vancomycin dose in the PICU were evaluated in this retrospective chart review. AKI was defined based on Pediatric-Modified RIFLE (pRIFLE) criteria. Patient demographics, vancomycin trough concentrations, concomitant nephrotoxins, and estimated creatinine clearance changes were analyzed.RESULTS:Of 265 patients included, the primary outcome of AKI (defined by meeting any pRIFLE criteria) occurred in 62 (23.4%) patients (48 category R, 11 category I, 3 category F). Patients who received vancomycin treatment for = 5 days were more likely to develop AKI (unadjusted odds ratio [uOR]: 2.52; 95% confidence interval [CI]: 1.11-5.73), as were patients with a maximum vancomycin trough level = 20 mg/L (OR: 2.99; 95% CI: 1.54-5.78) and patients on 1 (uOR: 2.29; 95% CI: 1.12-4.66) or more concurrent nephrotoxin (uOR: 3.11; 95% CI: 1.43-6.77). Among nephrotoxins, patients receiving furosemide concomitantly with vancomycin were more likely to develop AKI (uOR: 3.47; 95% CI: 1.92-6.27). After adjustment, only furosemide was a significant predictor of risk of AKI/AKI (adjusted OR: 3.52; 95% CI: 1.88-6.62). The study was limited by its retrospective and observational design, and confounding variables.CONCLUSIONS:Patients who were receiving vancomycin with concurrent furosemide were at highest risk of developing AKI.
authors.affiliation: Department of Pharmacy, Alberta Health Services, University of Calgary, Calgary, Alberta.
authors.forename: Sarah
authors.initials: S
authors.lastname: Bonazza
authors.affiliation: Department of Pharmacy, Alberta Health Services, University of Calgary, Calgary, Alberta ; Department of Community Health Sciences, University of Calgary, Calgary, Alberta.
authors.forename: Lauren C
authors.initials: LC
authors.lastname: Bresee
authors.affiliation: Department of Pharmacy, Alberta Health Services, University of Calgary, Calgary, Alberta.
authors.forename: Timothy
authors.initials: T
authors.lastname: Kraft
authors.affiliation: Department of Pediatrics, Faculty of Medicine, University of Calgary, Calgary, Alberta.
authors.forename: B Catherine
authors.initials: BC
authors.lastname: Ross
authors.affiliation: Department of Pharmacy, Alberta Health Services, University of Calgary, Calgary, Alberta.
authors.forename: Deonne
authors.initials: D
authors.lastname: Dersch-Mills
keywords: acute kidney injury; critical illness; drug monitoring; pediatrics; vancomycin